Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia

Kelly, Martha J., Pietranico-Cole, Sherrie, Larigan, J. Douglas, Haynes, Nancy-Ellen, Reynolds, Charles H., Scott, Nathan, Vermeulen, John, Dvorozniak, Mark +11 more·2014·Journal of Medicinal Chemistry
DOI 10.1021/jm4019299

Cited by (232)

Items 201–232 of 232

  1. SMALL-MOLECULE AGONISTS OF THYROID HORMONE RECEPTOR BETA (THR-β)
    David C. McGowan, Xuan G. Luong · 2025 · Medicinal chemistry reviews
  2. ANTIBODY-DRUG CONJUGATES IN ONCOLOGY: RECENT ACHIEVEMENTS AND CURRENT CHALLENGES
    Timothy B. Lowinger, Dorin Toader · 2025 · Medicinal chemistry reviews
  3. EXPLORING THE THERAPEUTIC LANDSCAPE OF MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS: ADVANCES IN SMALL-MOLECULE DISCOVERY
    Fionn O’Hara, Bernd Kuhn, Uwe Grether · 2025 · Medicinal chemistry reviews
  4. EMERGING MEDICINAL CHEMISTRY APPROACHES TO MODULATE TRANSCRIPTIONAL ACTIVITY BY ACETYLATION
    Victoria D. Kutilek, Tamara D. Hopkins, Margaret M. Biddle · 2025 · Medicinal chemistry reviews
  5. DEVELOPMENT OF E3 LIGANDS TO ENABLE NEXT-GENERATION DEGRADERS
    Karli Holman, Westley F. Tear · 2025 · Medicinal chemistry reviews
  6. SMALL-MOLECULE MODULATORS OF CYTOKINE-RECEPTOR INTERACTIONS
    W. Liu, Ge Zou · 2025 · Medicinal chemistry reviews
  7. RECENT DISCOVERY EFFORTS TARGETING INHIBITION OF HEMATOPOIETIC PROTEIN KINASE 1 (HPK1) AS A NOVEL CANCER IMMUNOTHERAPY
    Rebecca A. Gallego, Neelu Kaila, David N. Ciccone · 2025 · Medicinal chemistry reviews
  8. RECENT ADVANCES IN WERNER HELICASE (WRN) INHIBITION FOR MICROSATELLITE INSTABILITY-HIGH CANCERS
    Lindsey G. DeRatt, Francis W. Hunter, Scott D. Kuduk · 2025 · Medicinal chemistry reviews
  9. 2025 Medicinal Chemistry Reviews
    2025 · Medicinal chemistry reviews
  10. TO MARKET, TO MARKET—2024: MACROMOLECULAR THERAPEUTICS
    Shion An Lim, Nicholas J. Agard, James R. Byrnes, Ryan L. Kelly, Santhosh K. Thatikonda, Benjamin N. Bell, Diana J. Wang, Si-Jie Chen, Ivelisse Cruz‐Torres, Anna M. Gram et al. · 2025 · Medicinal chemistry reviews
  11. NAVIGATING CHALLENGES IN ORAL HETEROBIFUNCTIONAL DEGRADERS: INSIGHTS AND STRATEGIES FOR EARLY-STAGE PROJECTS
    Tezcan Güney, Anh T. Tran, Katie Stamp · 2025 · Medicinal chemistry reviews
  12. MOLECULES, MENTORS, AND MOMENTS THAT MATTERED
    Wendy B. Young · 2025 · Medicinal chemistry reviews
  13. Efficacy and Safety of Pemvidutide in Patients with Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Dose-Specific Meta-Analysis of Randomized Controlled Trials
    Ehab Abdu, Raghad Alghamdi, Alaa Mohsen, Zahra Mohammed Alabbad, Mazin Ayman Kharabah, Anas Al-Thagfi, Mawadah Al-Shabeeb, Faisal Mohammed Alanzi, Hanan Al-Harthi, Ali Alessa et al. · 2025 · medRxiv
  14. Prise en charge clinique et thérapeutique des hépatopathies stéatosiques associées à une dysfonction métabolique (MASLD)
    Anne Tailleux, Saı̈d Kamel · 2026 · Revue Francophone des Laboratoires
  15. [New ways in interdisciplinarity: internal medicine meets human genetics : When frequent conditions become rare and rare conditions become frequent].
    L. Möller, Ann-Kathrin Schörding, Frank J. Kaiser, M. Nöthen, E. Mack, A. Neubauer · 2026 · Innere Medizin
  16. Development and validation of a novel analytical method for related substances of resmetirom and identification of new degradation products
    Jisu Qin, Qunfeng Luo, Wenyi Wu, Qin Wang, Liangliang Cai, Shuang Wang, Yonghong Zhu · 2026 · Frontiers in Chemistry
  17. Influence du sexe dans la susceptibilité aux hépatopathies métaboliques
    Sarra Smati · 2019 · theses.fr (ABES)
  18. Estimation of rezdiffra (MGL-3196) by validated RP-HPLC approach in bulk material and pharmaceutical formulation
    Md. Abid Hasan, Raisa Tasnim Simran, Ejaj Sumit, Musfirat Tania, Maria Kibtia Ali · 2026 · Drug Development and Industrial Pharmacy
  19. Emerging metabolic hormone therapeutics for metabolic dysfunction-associated steatohepatitis: incretin-based drugs, fibroblast growth factor analogs, and liver-targeting strategies
    Sukwoo Han, Jaehee Shin, Jae Cheon Kim, Dong Hee Na · 2026 · Journal of Pharmaceutical Investigation
  20. Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASH
    Woonghee Kim, Mengzhen Li, Xinmeng Liao, Sevilay Özmen, Edanur Yıldız, Melik Saraçoğlu, Cem Baba, Fatih Çağlar Çelikezen, Said Ali Atalay, Ahmet Tuğrul Akkuş et al. · 2026 · Frontiers in Pharmacology
  21. Discovery of Potent and Selective THRβ Agonists Based on an N -Benzoylglycine Scaffold for the Treatment of Metabolic Disorders
    Yue Wu, Linjian Zhang, X Q Li, 曹瑞恆, Shuang Han, Shanrui Li, Wei Shen Aik, Haoshu Zhang, Peiyao Yang, Tiande Bing et al. · 2026 · Journal of Medicinal Chemistry
  22. Adipose Tissue Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Andrew John Legaspi Cruz, Liyun Yuan · 2026 · Cells
  23. Resmetirom Ameliorates Fibrogenesis in Hepatic Stellate Cells via Thyroid Hormone Receptor Alpha‐Fatty‐Acid Amide Hydrolase 1 Signaling Pathway
    Eva Nóvoa, Alba Cabaleiro, Borja López-Picallo, Natália da Silva Lima, C Riobello, Carmen Pena, Jose Iglesias-Moure, Ana Senra, Maria Luz Martínez‐Chantar, Anabel Fernández‐Iglesias et al. · 2026 · MedComm
  24. The role of thyroid hormone beta 1 receptor (THRβ1) in metabolic dysfunction associated steatohepatitis (MASH): from dysregulation to therapeutic target.
    R. Patil, G. Viswanatha, Sai Balaji Andugulapati, S. Bojja, Arvinda Pai, N. D. Satyanarayan, K. Nandakumar · 2026 · Biochemical Pharmacology
  25. Effects of MASH risk genotypes on resmetirom efficacy in patients with MASH and fibrosis
    Naga Chalasani, Rebecca A. Taub, Robin Mogg, Dominic Labriola, Raul C. Camacho, Hang Zhang, Quentin Mark Anstee · 2026 · Journal of Hepatology
  26. Potential for Cardiovascular Benefits of Resmetirom Based on LDL-Cholesterol and Lipoprotein(a) Lowering Consistent Across Statin Subgroups, a Secondary Analysis of the MAESTRO-NASH Phase 3 Clinical Trial
    Meena B. Bansal, Rebecca A. Taub, Dominic Labriola, David G. Soergel, Yestle Kim, Naim Alkhouri, Mazen Noureddin, Seth Baum, Rohit Loomba · 2026 · Journal of clinical lipidology
  27. AI-Driven Discovery Pipeline Identifies Carvedilol as a Novel Partial Agonist of THRβ
    Shuai Han, Chaochun Wei, Han Ju, Tongyu Huo, Tzumei Wang, Yameng Liu, Chao Wang, Zhenming Liu, Xiaodong Dou, Ning Jiao · 2026 · Journal of Chemical Information and Modeling
  28. BindingDB Entry 50048146: The therapeutic journey of pyridazinone.
    BindingDB · 2018 · UC San Diego
  29. BindingDB Entry 50022101: Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH.
    BindingDB · 2025 · UC San Diego
  30. BindingDB Entry 50017868: Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
    BindingDB · 2023 · UC San Diego
  31. BindingDB Entry 50007641: The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
    BindingDB · 2021 · UC San Diego
  32. BindingDB Entry 50018825: Discovery of Highly Potent and Selective Thyroid Hormone Receptor β Agonists for the Treatment of Nonalcoholic Steatohepatitis.
    BindingDB · 2024 · UC San Diego